Supernus Pharmaceuticals Inc (SUPN)

24.63
2.05 7.68
NASDAQ : Health Care
Prev Close 26.68
Open 26.56
Day Low/High 24.32 / 26.68
52 Wk Low/High 9.51 / 23.30
Volume 756.35K
Avg Volume 578.30K
Exchange NASDAQ
Shares Outstanding 49.51M
Market Cap 1.32B
EPS 0.30
P/E Ratio 53.16
Div & Yield N.A. (N.A)

Latest News

Shark Bites: 5 Stocks I Am Playing in This Choppy Action

Shark Bites: 5 Stocks I Am Playing in This Choppy Action

Despite the unsettled market, there are still some interesting picks out there.

Supernus Pharmaceuticals (SUPN) Reaches New Lifetime High Today

Supernus Pharmaceuticals (SUPN) Reaches New Lifetime High Today

Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a new lifetime high candidate

Supernus Pharmaceuticals (SUPN) Is Today's Strong And Under The Radar Stock

Supernus Pharmaceuticals (SUPN) Is Today's Strong And Under The Radar Stock

Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a strong and under the radar candidate

Today's Strong And Under The Radar Stock Is Supernus Pharmaceuticals (SUPN)

Today's Strong And Under The Radar Stock Is Supernus Pharmaceuticals (SUPN)

Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a strong and under the radar candidate

Supernus Pharmaceuticals (SUPN) Is Today's Perilous Reversal Stock

Supernus Pharmaceuticals (SUPN) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a "perilous reversal" (up big yesterday but down big today) candidate

Supernus Pharmaceuticals (SUPN): Today's Weak On High Volume Stock

Supernus Pharmaceuticals (SUPN): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a weak on high relative volume candidate

Commit To Purchase Supernus Pharmaceuticals At $15, Earn 13.5% Annualized Using Options

Commit To Purchase Supernus Pharmaceuticals At $15, Earn 13.5% Annualized Using Options

Investors considering a purchase of Supernus Pharmaceuticals Inc shares, but tentative about paying the going market price of $19.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $15 strike, which has a bid at the time of this writing of $1.10.

Supernus Pharmaceuticals (SUPN) Shares Cross Below 200 DMA

Supernus Pharmaceuticals (SUPN) Shares Cross Below 200 DMA

In trading on Wednesday, shares of Supernus Pharmaceuticals Inc crossed below their 200 day moving average of $15.71, changing hands as low as $15.28 per share. Supernus Pharmaceuticals Inc shares are currently trading off about 6.2% on the day.

SUPN Crosses Above Key Moving Average Level

SUPN Crosses Above Key Moving Average Level

In trading on Friday, shares of Supernus Pharmaceuticals Inc crossed above their 200 day moving average of $15.80, changing hands as high as $16.33 per share. Supernus Pharmaceuticals Inc shares are currently trading up about 6.3% on the day.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BC, BSFT, ECOL, FDX, LAND, SUPN, TX Downgrades: ENDP, USBI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Strong On High Relative Volume: Supernus Pharmaceuticals (SUPN)

Strong On High Relative Volume: Supernus Pharmaceuticals (SUPN)

Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a strong on high relative volume candidate

First Week of SUPN April 15th Options Trading

First Week of SUPN April 15th Options Trading

Investors in Supernus Pharmaceuticals Inc saw new options become available this week, for the April 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SUPN options chain for the new April 15th contracts and identified one put and one call contract of particular interest.

Supernus Prevails In Oxtellar XR® ANDA Litigation

Supernus Prevails In Oxtellar XR® ANDA Litigation

A Federal Court Finds Supernus Patents Valid and Actavis Infringing Two of Them